Cargando…

“Daily life of CAPS patients treated with canakinumab (Ilaris(®)) : data from the French observational study - ENVOL Study”

Detalles Bibliográficos
Autores principales:	Koné-Paut, I, Quartier, P, Fain, O, Grateau, G, Pillet, P, Le Blay, P, Bonnet, F, Despert, V, Stankovic, K, Willemins, L, Queré, S, Reigneau, O, Hachulla, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4600039/ http://dx.doi.org/10.1186/1546-0096-13-S1-P162

Ejemplares similares

French Amyloidosis CAPS study: AA Amyloidosis complicating cryopyrin-associated periodic syndrome: a study on 14 cases and review of 53 cases from literature
por: Georgin-Lavialle, S, et al.
Publicado: (2015)

P02-027 - Quality of life in CAPS treated by Canakinumab
por: Marsaud, C, et al.
Publicado: (2013)

A survey of resistance to colchicine treatment for French patients with familial Mediterranean fever
por: Corsia, Alice, et al.
Publicado: (2017)

Brookhaven : L'envol de PHENIX
Publicado: (1992)

Arthrite juvénile idiopathique et Covid-19 : impact de la pandémie sur le traitement et le retour à l’école
por: Quéré, B., et al.
Publicado: (2021)

Interleukin-1 antagonists in Mevalonate Kinase Deficiency
por: Galeotti, C, et al.
Publicado: (2011)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Pharmacokinetics of Canakinumab in children younger than 2 years old with CAPS
por: Kalabus, J, et al.
Publicado: (2015)

PW02-041 - Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

PReS-FINAL-2224: Canakinumab treatment regimens in CAPS-patients
por: Hofer, F, et al.
Publicado: (2013)

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
por: Gautier, A, et al.
Publicado: (2013)

PReS-FINAL-2231: A series of 41 mutations of TNFRAF1A
por: Chastang, MC, et al.
Publicado: (2013)

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients
por: Bader-Meunier, B, et al.
Publicado: (2011)

Juvenile Idiopathic Arthritis and COVID-19 Pandemic: Good Compliance With Treatment, Reluctance to Return to School
por: Quéré, Baptiste, et al.
Publicado: (2021)

Canakinumab treat-to target strategies increase complete response rate in CAPS
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

Le C.E.R.N. s'envole vers des énergies plus élevées
Publicado: (1995)

Efficacy, safety, and post-vaccination antibody titer data in children with CAPS treated with Canakinumab
por: Brogan, P, et al.
Publicado: (2015)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
por: Koné-Paut, Isabelle, et al.
Publicado: (2011)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

PW02-016 - 41 cases of TRAPS, a rare autoinflammatory disease
por: Chastang, M-C, et al.
Publicado: (2013)

Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS)
por: Toker, Ori, et al.
Publicado: (2010)

Vasculitis associated with familial Mediterranean fever: a study on 16 french adult cases
por: Abbara, S, et al.
Publicado: (2015)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS)
por: Mamoudjy, Nafissa, et al.
Publicado: (2017)

Canakinumab in the routinary clinical practice in cryopyrin-associated periodic syndromes (CAPS): one year of follow-up
por: Caorsi, R, et al.
Publicado: (2011)

Long-Term Follow-Up and Optimization of Interleukin-1 Inhibitors in the Management of Monogenic Autoinflammatory Diseases: Real-Life Data from the JIR Cohort
por: Hentgen, Véronique, et al.
Publicado: (2021)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Creation of a cohort of French patients with chronic recurrent multifocal osteitis : preliminary results
por: Wipff, J, et al.
Publicado: (2011)

Long-term efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever: results from the randomised phase III CLUSTER trial
por: Ozen, Seza, et al.
Publicado: (2020)

Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study
por: Vigué, Bernard, et al.
Publicado: (2016)

P02-009 - Candle syndrome: expanding spectrum
por: Kone-Paut, I, et al.
Publicado: (2013)

Rapid and Sustained Long‐Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin‐Associated Periodic Syndrome Ages Five Years and Younger
por: Brogan, Paul A., et al.
Publicado: (2019)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
por: Saperia, C, et al.
Publicado: (2015)

Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
por: Kuemmerle-Deschner, J, et al.
Publicado: (2015)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jert6fk6ge7gq5rn4f5mclcg0h